噬菌体展示抗体库筛选技术研究进展

噬菌体展示技术已成为制备高亲和力抗体的强有力的工具。而噬菌体抗体库的筛选是在获得高亲和力抗体过程中很关键的一个环节。总结了针对不同复杂程度的抗原所须采用的不同筛选方法,并简单介绍了高通量筛选的优势。     

噬菌体抗体库筛选技术研究进展

噬菌体抗体库技术是一项新兴的基因工程抗体技术,应用这项技术获得高特异性抗体的关键之一就是筛选环节。根据抗原性质以及筛选目的的不同,筛选方法的选择也不相同,各种筛选策略的优化对中和抗体的获得有至关重要的作用。     

噬菌体抗体库筛选技术

噬菌体展示技术（Ｐｈａｇｅ Ｄｉｓｐｌａｙ Ｔｅｃｈｎｏｌｏｇｙ）为制备高亲和性抗体提供了有力的工具。噬菌体抗体库的筛选是其中关键的环节,为了提高筛选效率,用包被在固体表面的抗原进行筛选的传统方法不断地被改进,如宿主菌直接洗脱和双层膜筛选系统和抗抗体替代抗原筛选系统。将噬菌体感染宿主菌的过程与筛选过程相关联,产生了选择性感染筛选系统。     

噬菌体抗体库筛选技术

在过去的20年中,噬菌体抗体库筛选技术被广泛的应用于抗体筛选、疾病治疗,临床诊断以及基础研究之中。在该技术的应用过程中,快速有效的筛选出最适合的单克隆抗体并进行可靠和高效的数据管理和分析是十分重要的。文中总结了近年来噬菌体抗体库的高通量筛选方法并且对数据管理做了简要介绍。     

基于细胞的噬菌体抗体库筛选技术

肿瘤细胞表面抗原的表达量低,免疫原性弱,因抗原构象改变的原因,用传统的固定化抗原方法很难获得有价值的噬菌体抗体。这类抗原大多具有复杂的结构,且其转运、定位与细胞类型及所处的微环境有关。在基于细胞的筛选中,靶抗原以天然状态存在,不需纯化,甚至可以对未知抗原进行筛选,因此广泛用于对内化抗体和血管内皮抗原表位抗体的筛选。基于细胞的抗体筛选中的主要问题是因非特异结合造成的选择背景过高,迄今,已有许多旨在改善选择灵敏度和特异性的研究开展起来。随高通量流式细胞术、组合化学及蛋白质组学研究技术在细胞筛选中的运用,必将使其日趋实用和成熟。我们拟以细胞和组织筛选的技术做一概括,为了解基于细胞的筛选和优化设计提供参考。     

链替换技术提高噬菌体抗体亲和力的研究进展

高亲和力抗体基因的克隆是噬菌体抗体在基础研究、临床诊断治疗研究等重要领域中应用的基础。链替换技术已逐步广泛用于噬菌体抗体的性能改造。该技术不仅可以促进噬菌体的体外亲和力成熟,提高抗体亲和力,有助于低剂量抗体达到实际应用所需要的抗原结合效应,拓宽抗体的应用开发前景,而且可应用于减少抗体人抗鼠抗体反应,分析重链或轻链基因对抗原抗体结合的影响,有助于较好的理解免疫化学。就链替换的原理、策略及其应用进行综述。     

肿瘤特异性蛋白B7-H4纳米抗体的筛选和鉴定

羊驼体内存在天然缺少轻链的重链抗体,克隆重链抗体可变区(VHH),即可构建单域抗体(single-domain antibodies,sdAbs),又称纳米抗体(nanobody,Nb)。利用非免疫羊驼噬菌体文库筛选肿瘤特异性蛋白B7-H4的纳米抗体,经过4轮淘选,ELASE鉴定阳性克隆噬菌体,测序获得其DNA序列后体外转录为mRNA,将修饰纯化后的mRNA转染到肿瘤细胞,利用细胞免疫荧光检测mRNA在肿瘤细胞内是否表达,Western印迹进一步验证其表达情况;通过CCK-8法鉴定其对肿瘤细胞的增殖抑制能力;划痕实验鉴定其对肿瘤细胞迁移能力的影响;Transwell法鉴定其对肿瘤细胞的侵袭能力的影响;裸鼠荷瘤模型瘤旁注射mRNA,鉴定其在体内实验对肿瘤组织的作用。结果显示,通过淘选获得1个高亲和性的噬菌体株菌H6;DNA测序并导出的氨基酸序列符合羊驼纳米抗体结构;将其mRNA导入肿瘤细胞,能有效表达出纳米抗体H6;转染H6-mRNA的肿瘤细胞(0.84±0.08)与未转染H6-mRNA的对照组(1.83±0.04)相比,其增殖能力明显受到抑制,P<0.01,其迁移和侵袭能力(78.60±5.36)明显低于空白对照组(197.80±21.04),效果优于B7-H4 mRNA的siRNA(95.40±16.56);在裸鼠乳腺癌模型中能有效抑制肿瘤生长,效果优于紫杉醇和B7-H4 mRNA的siRNA。这说明筛选所得抗B7-H4纳米抗体H6能特异结合B7-H4蛋白并封闭其功能,导致肿瘤细胞的增殖、迁移和侵袭受到抑制。该结果为利用B7-H4作为治疗癌症的靶点提供了实验基础。     

双峰驼源天然噬菌体纳米抗体展示库的构建及抗GDH纳米抗体筛选

目的:构建噬菌体天然纳米抗体展示库,以期用于筛选不同抗原分子的纳米抗体筛选平台,并用艰难梭菌谷氨酸脱氢酶(GDH)抗原筛选靶向GDH的纳米抗体,对所构建的噬菌体天然纳米抗体展示库进行验证。方法:采用Oligo DT提取双峰骆驼脾脏总RNA进行反转录,通过巢氏PCR获取全套重链可变区基因,将其构建到噬菌粒pCANTAB5E载体,经多次电转化至E. coil TG1构建初级噬菌体抗体库,经辅助噬菌体拯救后构成噬菌体展示库,并对噬菌体展示库的库容及多样性进行分析和鉴定。同时以GDH为靶向抗原对文库进行淘筛,计算淘筛回收率,并对第三轮淘筛后平板的单克隆进行ELISA鉴定。结果:构建的天然噬菌体纳米抗体库的插入率为95%左右,随机挑取的9个克隆氨基酸同源性为66. 17%,经MEGA分析后具有较好的多样性,同时经辅助噬菌体拯救后,得到的噬菌体展示库滴度为4×10~(12)CFU/ml。在三轮淘筛过程中,回收率逐步升高,噬菌体得到了有效的富集,同时对阳性克隆进行测序及分析,最终得到2条抗GDH纳米抗体序列。结论:成功构建了双峰驼源天然噬菌体纳米抗体展示文库且多样性良好,为后续筛选其他的靶向抗原奠定了基础,同时筛选获得两条抗GDH纳米抗体序列,为制备艰难梭菌谷氨酸脱氢酶诊断抗体提供技术支撑。     

抗c-Myc标签纳米抗体的筛选与应用

目的: 以c-Myc-GST蛋白为靶分子,从纳米抗体噬菌体展示免疫文库中筛选能够特异性识别c-Myc标签(EQKLISEEDL)的纳米抗体。方法: 采用固相淘选技术,筛选出能与c-Myc标签特异性结合的噬菌体,phage-ELISA鉴定阳性克隆并测序,通过基因重组技术将阳性噬菌体编码的纳米抗体基因克隆至原核表达载体pET25b(+),再转化至大肠杆菌Rosetta(DE3),IPTG诱导表达,SDS-PAGE分析重组蛋白表达情况。采用间接ELISA和量子点免疫荧光法验证纳米抗体的结合活性和特异性。结果: 通过4轮固相淘选,具有结合活性的噬菌体克隆得到了有效富集,回收率提高了145倍,阳性率从20.83%提高至85.4%。将phage-ELISA鉴定显色值高的两个纳米抗体A25和A26分别进行了重组表达,SDS-PAGE结果显示均为可溶性表达,表达量为60 mg/L。间接ELISA结果表明重组蛋白A25和A26都能够识别c-Myc标签,量子点免疫荧光法验证得到纳米抗体A25能够对SP2/0细胞内的c-Myc蛋白进行检测。结论: 成功地筛选出与c-Myc标签结合的纳米抗体噬菌体克隆,构建了两个抗c-Myc标签纳米抗体的原核表达载体并实现了可溶性表达,为检测胞内c-Myc蛋白奠定了基础。     

抗IL-5纳米抗体筛选及活性检测

白介素-5(IL-5)是一种同源二聚体细胞因子,是嗜酸性粒细胞(eosinophilic, EOS)增殖、活化和成熟的重要调节因子。抗IL-5单克隆抗体能阻断IL-5与IL-5受体亚单位α(IL-5Rα)结合,已成功用于治疗嗜酸性粒细胞哮喘。目前上市的单克隆抗体药物需要反复注射给药,严重影响了患者的依从性,而且注射给药的全身暴露率高。为获得适合吸入给药的抗体,在羊驼天然库中通过3轮淘选,挑取单克隆通过Phage ELISA初筛,共获得461个阳性克隆,其中50个为序列独特的分子,最终选择30个分子进行重组表达纯化。通过ELISA结合、ELISA阻断、FACS阻断、TF-1增殖抑制等实验对候选抗体进行体外活性检测,成功获得一个具有阻断IL-5和IL-5Rα结合的纳米抗体AIL-A96-Fc。通过与人和猴IL-5的ELISA结合实验表明,该分子具有良好人猴交叉活性,而且在FACS阻断实验和ELISA阻断实验中,AIL-A96-Fc表现出良好的阻断效果。该开发方法不仅提供了一个靶向IL-5的候选纳米抗体AIL-A96-Fc,也为后续开发更多靶向IL-5的候选纳米抗体提供了指导意义。     

In vitro tests for screening of immuno-modulating mycobacterial strains in leprosy

There is an urgent need for the development of anin vitro assay for the initial screening of a large number of organisms from which potential candidates as vaccines can be identified. Our previous studies have demonstrated a crucial defect in the lepromatous macrophage. In this study by monitoring this defective macrophage response we have screened various mycobacteria for their ability to reverse the alterations induced byMycobacterium leprae. Among the limited Mycobacteria testedMycobacterium vaccae appears to be the most promising as an immunomodulator. Our results also indicate the need for caution in using the mouse model for this purpose     

SARS-CoV-2中和纳米抗体在里氏木霉中的重组表达北大核心CSCD

基于骆驼科动物单链抗体VHH结构域的纳米抗体具有分子量小、结构简单、溶解性好、稳定性强等多种优势,可通过吸入给药,在呼吸道病毒的防控中具有重要应用价值。里氏木霉是食品级的蛋白质生产宿主,其纤维素酶分泌量可达到80 g/L以上,有望用于药物蛋白的低成本生产。文中在密码子优化的基础上,使用组成型强启动子Pcdna1,实现了SARS-CoV-2中和纳米抗体Nb20在里氏木霉中的重组表达。将Nb20与里氏木霉纤维二糖水解酶CBHⅠ的N端片段融合表达,并在二者间引入胞内KEX2蛋白酶切位点,于葡萄糖培养基中摇瓶发酵48 h可生产出浓度为47.4 mg/L的Nb20蛋白。重组表达的纳米抗体能够与SARS-CoV-2刺突蛋白的受体结合区相结合,有望用于新型冠状病毒的中和。以上结果显示,里氏木霉在纳米抗体的重组表达中具有一定的应用潜力。     

Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody

Animal‐derived anti‐IgG secondary antibodies are currently employed to stain and screen of human monoclonal antibody(mAb)‐producing cells, but using animal‐derived antibodies may raise the concerns of high cost, complicated operations and biological safety issues in biopharmaceutical manufacturing. Nanobodies(VHHs) are attractive forms of antibodies for their straightforward engineering and expression in both eukaryotic and prokaryotic systems. Using phage‐displayed immune llama VHH library, we identified new anti‐Fc VHHs that could bind to human Fc with high affinity. In GFP fusion format, the anti‐Fc VHH‐GFP generated dramatically stronger FACS signals than AF488 conjugated anti‐IgG antibodies when used for staining mAb‐producing CHO cells. Furthermore, preparative sorting of CHO cells based on anti‐Fc VHH‐GFP staining resulted in the enrichment of cell lines capable of synthesizing mAb at high productivity. This safe and cost‐efficient anti‐Fc VHH‐GFP may optimize the process of generating highly productive cell lines for therapeutic mAb production compared to conventional animal‐derived fluorescent antibodies.     

Development of a Plasmid Display System using GAL4 DNA Binding Domain for the <Emphasis Type="Italic">in Vitro</Emphasis> Screening of Functional Proteins

A plasmid display system using GAL4 DNA binding domain (GAL4 DBD) was constructed to enrich the molecular diversity and in vitro selection of functional proteins. Model proteins used were enhanced green fluorescent protein (EGFP) and glutathione S-transferase (GST). The feasibility of this display system was examined using enrichment experiments of target protein from a model protein mixture and identifying the encoding genes by PCR, in which the model protein mixture includes GAL4 DBD/GST fusion protein, GAL4 DBD/EGFP fusion protein, and xylanase. Target proteins of GAL4 DBD/GST and GAL4 DBD/EGFP from the model protein mixture were efficiently isolated by the plasmid display, respectively. The results show that the display system is sufficiently sensitive to select a target protein from a protein mixture, and that it is possible to discover the functional proteins from large libraries using relatively simple approaches.     

综述与专论: 核酸适配体筛选与亲和力评价技术主要研究方向、进展与挑战

核酸适配体是一类具有特异性分子识别能力的单链DNA或者RNA分子,通过指数富集的配体系统进化技术（SELEX）筛选得到。核酸适配体相比抗体具有热稳定性高、便于化学合成与修饰、免疫原性低等优点,在生物分析、生物医学、生物技术等众多领域引起广泛关注。高质量的核酸适配体是应用的基础,然而目前能够满足实际应用的核酸适配体数量还非常有限。如何获得高亲和力、高特异性、高体内稳定性的核酸适配体是核酸适配体领域的技术瓶颈。本文首先简单介绍了SELEX技术的基本原理和核酸库的设计、筛选过程监控、次级文库制备、测序和候选适配体筛选等关键步骤。接着归纳总结了30多年来核酸适配体筛选技术的6个主要研究方向、研究进展和局限性。这6个主要研究方向分别是提高适配体特异性的筛选方法、提高适配体稳定性（抗核酸酶降解能力）的筛选方法、快速筛选方法、复杂靶标适配体筛选方法、小分子靶标适配体筛选方法、提高适配体亲和力的筛选方法。其中快速筛选技术是长期以来持续关注的研究方向,几乎所有物理分离手段都已用于提高SELEX的筛选效率。最近,高效化学反应与SELEX技术的结合为核酸适配体的快速筛选提供了新的策略。本文随后对适合小分子靶标核酸适配体筛选的3类方法进展和存在的问题进行了重点评述。这3类方法分别是基于靶标固定的筛选技术、基于文库固定的筛选技术（捕获-SELEX,Capture-SELEX）和均相筛选技术（氧化石墨烯-SELEX,GO-SELEX）。基于靶标固定的筛选技术尽管存在空间位阻等众多问题,由于其操作的简单性,目前依然应用广泛。近年来Capture-SELEX应用广泛。结合36种靶标适配体的筛选实验条件（文库设计、正筛靶标浓度、负筛靶标的选择和浓度）和所获得的适配体的亲和力（K_D,解离常数,dissociation constant）和特异性,对Capture-SELEX的实验条件与适配体性能的关系进行了讨论。统计数据表明,降低正筛靶标浓度有利于提高适配体的亲和力,但不是必要条件。负筛选是目前提高适配体特异性的主要技术手段,但适配体的特异性还不能满足实际需求。负筛选靶标及其浓度的选择差异很大,而且36种靶标中有20种靶标的适配体筛选没有进行负筛选。如何提高核酸适配体的特异性是目前小分子靶标核酸适配体所面临的难题,急需寻找新的策略。本文还列表归纳了近三年利用GO-SELEX进行的13种小分子靶标的实验条件和所获得的适配体的K_D和特异性。统计数据表明,GO-SELEX比Capture-SELEX所需要的筛选轮数少,两种方法所获得的适配体的亲和力多在纳摩尔每升水平。Capture-SELEX相对较低的筛选效率应该主要由于文库的自解离问题。核酸适配体的亲和力评价是候选核酸适配体结构与性能评价的重要组成部分。常用的核酸适配体亲和力评价技术包括基于分离、基于固定、均相体系三大类十多种方法。假阳性和假阴性是各种评价技术都有可能存在的问题。本文以纳米金比色法和等温热滴定技术为例评述技术进展,讨论导致不同亲和力评价技术结果不一致性问题的根本原因。本文最后对核酸适配体筛选技术、亲和力评价技术和技术的标准化的未来发展趋势进行了展望。     

Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches

Epidermal growth factor receptor (EGFR), a transmembrane glycoprotein, is overexpressed in many cancers such as head-neck, breast, prostate, and skin cancers for this reason it is a good target in cancer therapy and diagnosis. In nanobody-based cancer diagnosis and treatment, nanobodies with high affinity toward receptor (e.g. EGFR) results in effective treatment or diagnosis of cancer. In this regard, the main aim of this study is to develop a method based on molecular dynamic (MD) simulations for designing of 7D12 based nanobody with high affinity compared with wild-type nanobody. By surveying electrostatic and desolvation interactions between different residues of 7D12 and EGFR, the critical residues of 7D12 that play the main role in the binding of 7D12 to EGFR were elucidated and based on these residues, five logical variants were designed. Following the 50 ns MD simulations, pull and umbrella sampling simulation were performed for 7D12 and all its variants in complex with EGFR. Binding free energy of 7D12 (and all its variants) with EGFR was obtained by weighted histogram analysis method. According to binding free energy results, GLY101 to GLU mutation showed the highest binding affinity but this variant is unstable after 50 ns MD simulations. ALA100 to GLU mutation shows suitable binding enhancement with acceptable structural stability. Suitable position and orientation of GLU in residue 100 of 7D12 against related amino acids of EGFR formed some extra hydrogen and electrostatic interactions which resulted in binding enhancement.     

Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites

We report two improved assays for in vitro and in vivo screening of chemicals with potential anti-malarial activity against the blood stages of the rodent malaria parasite Plasmodium berghei. These assays are based on the determination of luciferase activity (luminescence) in small blood samples containing transgenic blood stage parasites that express luciferase under the control of a promoter that is either schizont-specific (ama-1) or constitutive (eef1αa). Assay 1, the in vitro drug luminescence (ITDL) assay, measured the success of schizont maturation in the presence of candidate drugs quantifying luciferase activity in mature schizonts only (ama-1 promoter). The ITDL assay generated drug-inhibition curves and EC₅₀ values comparable to those obtained with standard in vitro drug-susceptibility assays. The second assay, the in vivo drug-luminescence (IVDL) assay, measured parasite growth in vivo in a standard 4-day suppressive drug test, monitored by measuring the constitutive luciferase activity of circulating parasites (eef1αa promoter). The IVDL assay generates growth-curves that are identical to those obtained by manual counting of parasites in Giemsa-stained smears. The reading of luminescence assays is rapid, requires a minimal number of handling steps and no experience with parasite morphology or handling fluorescence-activated cell sorters, produces no radioactive waste and test-plates can be stored for prolonged periods before processing. Both tests are suitable for use in larger-scale in vitro and in vivo screening of drugs. The standard methodology of anti-malarial drug screening and validation, which includes testing in rodent models of malaria, can be improved by the incorporation of such assays.     

血脑屏障体外模型研究进展

脑毛细血管上的特殊结构单元为大脑提供氧气和养分,与此同时形成一种限制性屏障,称为血脑屏障(BBB),该结构单元由单层脑微血管内皮细胞构成,内皮细胞外侧的周细胞、基膜以及星形胶质细胞的足突也参与了血脑屏障的形成.血脑屏障是一种选择性渗透屏障,大多数中枢神经系统候选药物在血脑屏障中的渗透性差,用实验动物进行药物筛选具有成本高、周期长、成功率低等缺点.此外,直接在人体中试验有违道德伦理,但建立可靠的体外血脑屏障模型可以简化实验过程、缩短试验周期、实验结果更易测定,因此建立体外BBB模型可以极大地加快中枢神经系统药物的研发.目前已研究的模型主要可以分为3类:单培养、共培养、三培养,这些模型由简单到复杂,与体内血脑屏障的相似性也越来越高.本文就目前现有的血脑屏障模型进行综述,以期未来在体外BBB模型设计中有新的思路.